Ophthotech, a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases, acquired Inception 4, a provider of pharmaceutical development services. Financial terms were not disclosed. “We are excited for Ophthotech to add the Inception 4 HtrA1 inhibitor program to its diversified portfolio,” stated Jerel Davis, Ph.D., Managing Director of Versant Ventures. “The Ophthotech team has unique expertise in drug development for retinal diseases, including a proven track record in conducting multiple global clinical trials, and we are pleased to have the HtrA1 inhibitor program as part of the next chapter of Ophthotech’s retinal franchise. As shareholders of Ophthotech, we look forward to the advancement of the HtrA1 inhibitor program as well as the rest of Ophthotech’s therapeutic and gene therapy portfolio.”